CLINICAL STUDIES ON BRL 28500 (CLAVULANIC ACID-TICARCILLIN)

BRL 28500, a formulation of ticarcillin (TIPC, 15 parts) and clavulanic acid (CVA, 1 part) was evaluated for clinical efficacy in 20 patients suffering from pneumonia (8), chronic bronchitis (2), acute cystitis (1), chronic cystitis (4), acute pyelitis (3) and chronic pyelitis (2). The clinical resp...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 34; no. Supplement4; pp. 371 - 378
Main Authors YOSHIDA, SHUICHIRO, YONETA, MASASHI, TAMURA, TOYOICHI, YASHIRO, HITOSHI, FUKUCHI, KAZUHIKO, SAGARA, MORIO, KASHIWAMURA, HIDEAKI, TAKEBE, KAZUO, OKAMOTO, KATSUHIRO, NAKAMURA, TERUO, BABA, MASAYUKI
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1986
公益社団法人 日本化学療法学会
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.34.Supplement4_371

Cover

Abstract BRL 28500, a formulation of ticarcillin (TIPC, 15 parts) and clavulanic acid (CVA, 1 part) was evaluated for clinical efficacy in 20 patients suffering from pneumonia (8), chronic bronchitis (2), acute cystitis (1), chronic cystitis (4), acute pyelitis (3) and chronic pyelitis (2). The clinical response was excellent in 7 patients, good in 12 and poor in 1. All strains of bacteria were eradicated following the administration of BRL 28500 including 3 that were considered ticarcillin-resistant. Against 2 of these resistant strains the MIC of BRL 28500 was determined. One strain (K. Oxytoca) was sensitive to BRL 28500 although the other strain (P.aeruginosa) appeared resistant. There were no side effects. Laboratory abnormalities were limited to a slight elevation of GOT, GPT, LDH and γ-GTP in 1 case.
AbstractList BRL 28500, a formulation of ticarcillin (TIPC, 15 parts) and clavulanic acid (CVA, 1 part) was evaluated for clinical efficacy in 20 patients suffering from pneumonia (8), chronic bronchitis (2), acute cystitis (1), chronic cystitis (4), acute pyelitis (3) and chronic pyelitis (2). The clinical response was excellent in 7 patients, good in 12 and poor in 1. All strains of bacteria were eradicated following the administration of BRL 28500 including 3 that were considered ticarcillin-resistant. Against 2 of these resistant strains the MIC of BRL 28500 was determined. One strain (K. Oxytoca) was sensitive to BRL 28500 although the other strain (P.aeruginosa) appeared resistant. There were no side effects. Laboratory abnormalities were limited to a slight elevation of GOT, GPT, LDH and γ-GTP in 1 case.
BRL 28500, a formulation of ticarcillin (TIPC, 15 parts) and clavulanic acid (CVA, 1 part) was evaluated for clinical efficacy in 20 patients suffering from pneumonia (8), chronic bronchitis (2), acute cystitis (1), chronic cystitis (4), acute pyelitis (3) and chronic pyelitis (2). The clinical response was excellent in 7 patients, good in 12 and poor in 1.All strains of bacteria were eradicated following the administration of BRL 28500 including 3 that were considered ticarcillin-resistant. Against 2 of these resistant strains the MIC of BRL 28500 was determined. One strain (K. Oxytoca) was sensitive to BRL 28500 although the other strain (P.aeruginosa) appeared resistant.There were no side effects. Laboratory abnormalities were limited to a slight elevation of GOT, GPT, LDH and γ-GTP in 1 case. BRL 28500の臨床効果を肺炎8例, 慢性気管支炎2例, 急性膀胱炎1例, 慢性膀胱炎4例, 急性腎盂腎炎3例および慢性腎盂腎炎2例を含む20例で検討した。結果は, 著効7例, 有効12例, 無効1例で, 全体の有効率は95%であった。呼吸器感染症の有効率は90%, 尿路感染症の有効率は100%であった。起炎菌と推定されたものは15株が見出され, 本剤投与によりすべて消失した。そのうちTIPC感受性を検討したのが13株で, TIPC耐性は3株であった。この3株のうち2株についてBRL 28500の感受性の検査を行ったところ, 1株がBRL 28500に感受性があり, 他の1株はBRL 28500に耐性であった。自他覚的副作用はみられなかった。臨床検査値は1例に本剤投与後にGOT, GPT, LDH, γ-GTPの軽度上昇が認められた。上記の結果より, BRL 28500は呼吸器および尿路感染症に対して優れた薬剤であり, 副作用, 臨床検査値異常をほとんど認めず, 有用な抗生剤である。
Author BABA, MASAYUKI
KASHIWAMURA, HIDEAKI
FUKUCHI, KAZUHIKO
TAKEBE, KAZUO
YASHIRO, HITOSHI
YOSHIDA, SHUICHIRO
SAGARA, MORIO
NAKAMURA, TERUO
OKAMOTO, KATSUHIRO
TAMURA, TOYOICHI
YONETA, MASASHI
Author_FL 米田 政志
岡本 勝博
八代 均
吉田 秀一郎
相楽 衛男
武部 和夫
馬場 正之
福士 一彦
柏村 英明
田村 豊一
中村 光男
Author_FL_xml – sequence: 1
  fullname: 武部 和夫
– sequence: 2
  fullname: 馬場 正之
– sequence: 3
  fullname: 中村 光男
– sequence: 4
  fullname: 米田 政志
– sequence: 5
  fullname: 岡本 勝博
– sequence: 6
  fullname: 吉田 秀一郎
– sequence: 7
  fullname: 相楽 衛男
– sequence: 8
  fullname: 福士 一彦
– sequence: 9
  fullname: 田村 豊一
– sequence: 10
  fullname: 八代 均
– sequence: 11
  fullname: 柏村 英明
Author_xml – sequence: 1
  fullname: YOSHIDA, SHUICHIRO
  organization: The Department of Internal Medicine, Hirosaki City Hospital
– sequence: 1
  fullname: YONETA, MASASHI
  organization: The Department of Internal Medicine, Itayanagi Central Hospital
– sequence: 1
  fullname: TAMURA, TOYOICHI
  organization: The Department of Internal Medicine, Hokushuu Central Hospital
– sequence: 1
  fullname: YASHIRO, HITOSHI
  organization: The Department of Internal Medicine, Hokushuu Central Hospital
– sequence: 1
  fullname: FUKUCHI, KAZUHIKO
  organization: The Department of Internal Medicine, Hirosaki City Hospital
– sequence: 1
  fullname: SAGARA, MORIO
  organization: The Department of Internal Medicine, Hirosaki City Hospital
– sequence: 1
  fullname: KASHIWAMURA, HIDEAKI
  organization: The Department of Internal Medicine, Hokushuu Central Hospital
– sequence: 1
  fullname: TAKEBE, KAZUO
  organization: The Third Department of Internal Medicine, Hirosaki University School of Medicine
– sequence: 1
  fullname: OKAMOTO, KATSUHIRO
  organization: The Department of Internal Medicine, Hirosaki City Hospital
– sequence: 1
  fullname: NAKAMURA, TERUO
  organization: The Department of Internal Medicine, Itayanagi Central Hospital
– sequence: 1
  fullname: BABA, MASAYUKI
  organization: The Department of Internal Medicine, Itayanagi Central Hospital
BackLink https://cir.nii.ac.jp/crid/1390282681257288832$$DView record in CiNii
BookMark eNpdkEtPwkAUhScGExH5D1240MTiPDszcVULapMJJDzcjtNykRIoTVsW_HuH4ELZ3JubfOfck3OLOuW-BISeCB4QQgV-ztew27drqF11JFqwAeOD2aGqtrCDsuWWSXKFukQpHgqleQd1McY6ZCQSN6jfNEWGMSE4oop20Uti0nGaxCaYzRfDdDQLJuPgdWoCqgTGwUNi4s-FiT0SxEk6DOeenSap8arHO3S9ctsG-r-7hxZvo3nyEZrJ-8ky3FDO2jCDpc8icpZhcM5_hQwUWdFcQrTSUSbFUvo8HhFaUSwy4JxoziMHUcadZD10f_Yti8LmxWkSprF3ipRvRFKlFKMe-zpjm6Z132Cruti5-mhd3Rb5Fuxlb5Zx-6-3i1OSP1JXWyjZDzZYb98
ContentType Journal Article
Copyright Japanese Society of Chemotherapy
Copyright_xml – notice: Japanese Society of Chemotherapy
DBID RYH
DOI 10.11250/chemotherapy1953.34.Supplement4_371
DatabaseName CiNii Complete
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate BRL 28500 (Clavulanic acid-Ticarcillin) の臨床使用経験
DocumentTitle_FL BRL 28500 (Clavulanic acid-Ticarcillin) の臨床使用経験
EISSN 1884-5894
EndPage 378
ExternalDocumentID 130004072481
article_chemotherapy1953_34_Supplement4_34_Supplement4_371_article_char_en
GroupedDBID 53G
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
JSF
JSH
KQ8
RJT
RZJ
ZOHVM
RYH
ID FETCH-LOGICAL-j243t-bed8845c3b0eaa282ebe81f2c7e6f96b75d7110845598205be4419446ae6b4a73
ISSN 0009-3165
IngestDate Fri Jun 27 00:41:44 EDT 2025
Wed Sep 03 06:29:37 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Issue Supplement4
Language English
Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j243t-bed8845c3b0eaa282ebe81f2c7e6f96b75d7110845598205be4419446ae6b4a73
OpenAccessLink https://www.jstage.jst.go.jp/article/chemotherapy1953/34/Supplement4/34_Supplement4_371/_article/-char/en
PageCount 8
ParticipantIDs nii_cinii_1390282681257288832
jstage_primary_article_chemotherapy1953_34_Supplement4_34_Supplement4_371_article_char_en
PublicationCentury 1900
PublicationDate 1986-00-00
PublicationDateYYYYMMDD 1986-01-01
PublicationDate_xml – year: 1986
  text: 1986-00-00
PublicationDecade 1980
PublicationTitle CHEMOTHERAPY
PublicationTitleAlternate Chemother.
PublicationTitle_FL ＣＨＥＭＯＴＨＥＲＡＰＹ
Chemother
PublicationYear 1986
Publisher Japanese Society of Chemotherapy
公益社団法人 日本化学療法学会
Publisher_xml – name: Japanese Society of Chemotherapy
– name: 公益社団法人 日本化学療法学会
References 3) 第33回日本化学療法学会総会, 新薬シンポジウム, BRL 28500 (Clavulanic acid-Ticarcillin). 1985, 東京
1) READING, C. & M. COLE: Clavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob. Agents Chemother. 11 (5): 852-857, 1977
2) PAISLEY, J. W. & J. A. WASHINGTON II: Combined activity of clavulanic acid and ticarcillin against ticarcillin-resistant, Gram-Negative bacilli. Antimicrob. Agents Chemother. 14 (2): 224-227, 1978
References_xml – reference: 2) PAISLEY, J. W. & J. A. WASHINGTON II: Combined activity of clavulanic acid and ticarcillin against ticarcillin-resistant, Gram-Negative bacilli. Antimicrob. Agents Chemother. 14 (2): 224-227, 1978
– reference: 3) 第33回日本化学療法学会総会, 新薬シンポジウム, BRL 28500 (Clavulanic acid-Ticarcillin). 1985, 東京
– reference: 1) READING, C. & M. COLE: Clavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob. Agents Chemother. 11 (5): 852-857, 1977
SSID ssib001106282
ssj0000626693
ssib058492509
ssib005879733
ssib008506721
Score 1.1912369
Snippet BRL 28500, a formulation of ticarcillin (TIPC, 15 parts) and clavulanic acid (CVA, 1 part) was evaluated for clinical efficacy in 20 patients suffering from...
SourceID nii
jstage
SourceType Publisher
StartPage 371
Title CLINICAL STUDIES ON BRL 28500 (CLAVULANIC ACID-TICARCILLIN)
URI https://www.jstage.jst.go.jp/article/chemotherapy1953/34/Supplement4/34_Supplement4_371/_article/-char/en
https://cir.nii.ac.jp/crid/1390282681257288832
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX CHEMOTHERAPY, 1986/11/20, Vol.34(Supplement4), pp.371-378
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1884-5894
  dateEnd: 19941231
  omitProxy: true
  ssIdentifier: ssj0000626693
  issn: 0009-3165
  databaseCode: KQ8
  dateStart: 19530101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1884-5894
  dateEnd: 20041231
  omitProxy: true
  ssIdentifier: ssj0000626693
  issn: 0009-3165
  databaseCode: DIK
  dateStart: 19530101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NjtMwELa6i4S4IBAgdmFRDhxAJSU_dhKLU-gWJdAmKJug7SlyEltqJQpadQ_whrwVYztJ08JhQXCJ2tjj1J7p-JuJZwah52AhYMcSwhSO4CYWLjUps5hJauY3xOJUR8gtEi8q8PtLcjka_RicWrreVpP6-2_jSv6Gq3AP-CqjZP-As_2gcAM-A3_hChyG6414PJ3Hic5noHHdOE3Gb7P52AmIZan3s_PwUzEPoZOsV31u5tA7m0oDPulcAF2Wgmi2SPNoloUfe3C7TC-i-DxUDtKoiKdRnKW7tmSWq6ZFeBFCv94FEC6KTDXk6TKVRD2J7JalarOL87SjaXQMXpuqWm0EsIHLwpj9kVJ1ZIR_boPFvu1pWgr6XdeBmHCtXIMAmyTQRY077du6MrWUqUqmyi2KB0rV1UVa2v3Z1SV_flX9AOaAYfXg58hXhBMXTwbDlv1ge0m2WxaWh9Sli8s96oOvvl3uSNkVCOURuuVI15DE5_GHHTK1ZbDqIDNa4FN_gLRl4sBBpjqAhRTmQ3t3IVB7Hu3rAsqVvY1edfN-fYNZA8Rag8EhM0kcbVarAYrK76G7rfljhHo299FozR6gN50cG60cG2ligBwbSo6NFzspNg6l-OVDVLyb5dPIbIt6mGsHu1uz4g2IAandyuKMwZKAFgls4dQ-9wT1Kp80vgxNwbJygGORigNgpxh7jHsVZr77CB1vvmz4Y2SAtcFsYQsiXA8D1qMVEFWUctwI5on6BC31jMuvOnNL-e_YfILOYBHLeiWvYEVJ14VM5Ud8Jwhglzz9j89-gu7If6V2BD5Fx9ura34G0HhbPVNC9xNOF601
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CLINICAL+STUDIES+ON+BRL+28500+%28CLAVULANIC+ACID-TICARCILLIN%29&rft.jtitle=CHEMOTHERAPY&rft.au=YOSHIDA%2C+SHUICHIRO&rft.au=YONETA%2C+MASASHI&rft.au=TAMURA%2C+TOYOICHI&rft.au=YASHIRO%2C+HITOSHI&rft.date=1986&rft.pub=Japanese+Society+of+Chemotherapy&rft.issn=0009-3165&rft.eissn=1884-5894&rft.volume=34&rft.issue=Supplement4&rft.spage=371&rft.epage=378&rft_id=info:doi/10.11250%2Fchemotherapy1953.34.Supplement4_371&rft.externalDocID=article_chemotherapy1953_34_Supplement4_34_Supplement4_371_article_char_en
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-3165&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-3165&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-3165&client=summon